Kangstem Biotech Co. Ltd., of Seoul, selected Masthercell Global Inc., a subsidiary of Germantown, Md.-based Orgenesis Inc., as its contract manufacturing partner for the European clinical trials of Furestem-AD, a cell therapy designed to treat atopic dermatitis. Terms of the deal weren't disclosed.